Drug labeling and packaging are the primary means of communicating essential information about a medicinal product to healthcare professionals and patients. Beyond the physical container, labeling encompasses all printed or electronic information that accompanies the product, including the prescribing information, patient package inserts, and container labels. Regulatory authorities review labeling content carefully because it defines the approved conditions of use and provides the safety information necessary for safe and effective prescribing.
What Is Drug Labeling?
Drug labeling is the comprehensive set of information that describes the drug’s approved uses, dosage, administration, safety profile, and handling instructions. In regulatory terms, the label refers to all printed or graphic matter on or accompanying the drug product. The labeling serves multiple audiences: physicians and pharmacists need complete scientific information for prescribing decisions; patients need understandable information for safe use; and regulators use labeling to define the legal scope of marketing authorization. False or misleading labeling is prohibited by law, and any change to approved labeling requires prior regulatory approval.
Prescribing Information Structure
The prescribing information (PI), known as the package insert or summary of product characteristics (SmPC) in Europe, follows a standardized structure defined by regulatory guidelines. In the United States, the PI is organized into seventeen sections, beginning with the boxed warning for serious risks, followed by indications and usage, dosage and administration, dosage forms and strengths, contraindications, warnings and precautions, adverse reactions, drug interactions, use in specific populations, drug abuse and dependence, overdosage, description, clinical pharmacology, nonclinical toxicology, clinical studies, references, and how supplied/storage and handling. The highlights section at the beginning provides a concise summary for quick reference. In the EU, the SmPC follows a similar but not identical structure with nine sections.
Patient Package Inserts
Patient package inserts, also called patient information leaflets (PILs) in Europe, are written in non-technical language to help patients understand their medication. The content includes what the medicine is used for, what to know before taking it, how to take it, possible side effects, and how to store it. Patient information must be tested for readability and comprehension with representative users. In Europe, the PIL must be available in the official language(s) of each member state where the product is marketed. The font size, layout, and legibility are regulated to ensure accessibility.
Container Labels
Container labels are affixed directly to the drug product packaging and must convey essential information in a limited space. Required elements include the brand and generic name, dosage strength, route of administration, expiration date, lot number, manufacturer name, and storage conditions. Labels for controlled substances must include the appropriate scheduling symbol. Unit-dose packaging labels require additional elements such as the National Drug Code (NDC) number for bar code scanning. The label design must ensure that critical information remains legible throughout the product’s shelf life, including after repeated handling.
Regulatory Requirements
Regulatory requirements for labeling differ between the United States and Europe. The FDA requires that PI be submitted and approved as part of the NDA and that all promotional labeling comply with the fair balance standard, presenting both benefits and risks in a balanced manner. The Physician Labeling Rule (PLR) format is mandatory for all drugs approved after 2006. In Europe, the EMA and national competent authorities review the SmPC, PIL, and labeling as part of the MAA, and a harmonized labeling approach applies across the European Union through the centralized procedure. Both regions require that labeling be updated when new safety information emerges, through prior approval supplements in the US and variations in the EU.
Serialization and Traceability
Serialization assigns a unique identifier to each saleable unit of a drug product, enabling tracking through the supply chain to combat counterfeiting and diversion. In the United States, the Drug Supply Chain Security Act (DSCSA) requires that prescription drug packages be serialized with a product identifier containing the NDC, serial number, lot number, and expiration date. In Europe, the Falsified Medicines Directive (FMD) requires similar serialization and an anti-tampering device. The serial numbers are stored in a central repository accessible by pharmacists and regulators for verification at the point of dispensing. Serialization also facilitates product recalls and helps identify suspect products.
Child-Resistant Packaging
Child-resistant packaging is required for prescription drugs and certain over-the-counter products to prevent accidental ingestion by children. The Poison Prevention Packaging Act (US) and corresponding EU regulations specify testing protocols for child-resistant closures, which must be verified through panels of children aged forty-two to fifty-one months and adult senior panels. The packaging must be difficult for young children to open but not unduly difficult for adults. Exceptions are available for elderly patients who request non-child-resistant packaging through a signed declaration. In addition to child resistance, unit-dose blister packaging provides individual dose protection and tamper evidence.
Conclusion
Drug labeling and packaging are far more than administrative formalities — they are critical components of drug safety and effective communication. Regulatory authorities scrutinize labeling content and packaging design to ensure that healthcare professionals and patients have the information they need to use medicines safely and effectively. Sponsors must invest in labeling expertise throughout development, as labeling negotiations with regulators are among the final and most consequential steps in the approval process.
